Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris

Circulation

Volumn 90, Issue 2, 1994, Pages 726-734

  Thadani, Udho ^a,d   Ezekowitz, Michael ^b   Fenney, Linda ^c   Chiang, Yu Kun ^c  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROCHE BIOSCIENCE   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

angina; exercise; ischemia; ranolazine

Indexed keywords

CORONARY VASODILATING AGENT; GLYCERYL TRINITRATE; PLACEBO; RANOLAZINE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXERCISE TEST; FEMALE; HEADACHE; HEART MUSCLE ISCHEMIA; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; VERTIGO;

EID: 0028016058     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.90.2.726     Document Type: Article

References (11)

1. Brown CM, Clarke B, Dye A, Fraser S, Kenny BA, Kilpatrick AT, Patmore L, Spedding M, Whiting RL. Pharmacological profile of ranolazine, a metabolic modulator active in ischaemia. Br J Pharmacol. 1988;93(suppl):248P. Abstract.
2. Essamri B, Rousseau MF, D'Hondt A-M, Ahn S, Detry J-M, Pouleur H. Novel antianginal agent increases exercise duration and pressure-rate product in patients receiving diltiazem or β blocker. Circulation. 1990;82(suppl III):III-393. Abstract.
3. Opie LH. Fuels: carbohydrates and lipids. In: Opie LH, ed. The Heart: Physiology and Metabolism. New York, NY: Raven Press; 1991:208-246.
4. Fouler H, Hue L, Harlow BJ, Rousseau MF. Metabolic pathways modulation: a new approach to treat myocardial ischemia? Circulation. 1989;80(suppl II):II-52. Abstract.
5. Veitch K, Hombroeckx A, Caucheteux D, Pouleur H, Hue L. Global ischaemia induces a biphasic response of the mitochondrial respiratory chain: anoxic pre-perfusion protects against ischaemic damage. Biochem J. 1992;281:709-715.
6. Clarke B, McCormack JG, Spedding M. The anti-ischaemic effects of ranolazine in guinea-pig heart are associated with increases in active pyruvate dehydrogenase. J Mol Cell Cordial. 1992;24(4 suppl):S52. Abstract.
7. Jain D, Dasgupta P, Hughes LO, Lahiri A, Rafferty EB. Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium. Eur J Clin Pharmacol. 1990;38:111-114.
8. Jain D, Lahiri A, Dasgupta P, Hughes LO, Raferty EB. RS-43285 (Syntex): a preliminary study of a unique anti-anginal agent. Clin Sci. 1987;73(S17):38P. Abstract.
9. Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, Pouleur H. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with β-blocker or diltiazem. J Cardiovasc Pharmacol. 1992;20:131-138.
10. SAS Institute Inc. SAS/STAT Users Guide, Release 6.06. Cary, NC: SAS Institute Inc; 1989.
11. Thadani U, Shapiro W, DiBianco R. Effect of long-term placebo therapy on angina frequency and exercise tolerance in patients with stable angina pectoris. Circulation. 1984;70(suppl II):II-44. Abstract.